These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23317974)

  • 1. Maintenance treatment of psoriasis with cyclosporine A: comparison between continuous and weekend therapy.
    Fernandes IC; Torres T; Selores M
    J Am Acad Dermatol; 2013 Feb; 68(2):341-2. PubMed ID: 23317974
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis.
    Yoon HS; Youn JI
    J Dermatolog Treat; 2007; 18(5):286-90. PubMed ID: 17852632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis.
    Yamauchi PS; Lowe NJ
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S135-8. PubMed ID: 16488328
    [No Abstract]   [Full Text] [Related]  

  • 4. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis.
    Chaidemenos GC; Mourellou O; Avgoustinaki N; Papakonstantinou M; Karakatsanis G; Katsambas A
    J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1203-8. PubMed ID: 17894706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine.
    Opmeer BC; Heydendael VM; De Borgie CA; Spuls PI; Bossuyt PM; Bos JD; De Rie MA
    Arch Dermatol; 2004 Jun; 140(6):685-90. PubMed ID: 15210458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preprandial vs. postprandial pharmacokinetics of cyclosporine in patients with psoriasis.
    Umezawa Y; Mabuchi T; Ozawa A
    Int J Dermatol; 2007 Aug; 46(8):880-2. PubMed ID: 17651179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cyclosporine and psoriasis: experience with 14 patients].
    Gajardo J
    Rev Med Chil; 1993 Dec; 121(12):1411-5. PubMed ID: 8085065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two cases of chronic lymphoproliferative disorders in psoriatic patients treated with cyclosporine: hairy cell leukemia and Waldenstrom macroglobulinemia.
    Fozza C; Dore F; Bonfigli S; Podda L; Longinotti M
    Eur J Dermatol; 2005; 15(4):271-3. PubMed ID: 16048757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris.
    Hashizume H; Ito T; Yagi H; Takigawa M; Kageyama H; Furukawa F; Hata M; Shirahama S; Tanaka M; Higashishiba T; Machida H; Tsushima T; Matsushita K
    J Dermatol; 2007 Jul; 34(7):430-4. PubMed ID: 17584318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of quality of life and clinical usefulness of cyclosporin administration in patients with nail psoriasis.
    Abe M; Syuto T; Yokoyama Y; Ishikawa O
    J Dermatol; 2011 Sep; 38(9):916-8. PubMed ID: 21352333
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclosporine: what clinicians need to know.
    Koo J; Lee J
    Dermatol Clin; 1995 Oct; 13(4):897-907. PubMed ID: 8785893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.
    Ho VC; Griffiths CE; Berth-Jones J; Papp KA; Vanaclocha F; Dauden E; Beard A; Puvanarajan L; Paul C
    J Am Acad Dermatol; 2001 Apr; 44(4):643-51. PubMed ID: 11260540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics in combination with nonbiologics: efficacy and safety.
    Stebbins WG; Lebwohl MG
    Dermatol Ther; 2004; 17(5):432-40. PubMed ID: 15379778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety of cyclosporine in the treatment of psoriasis.
    Grossman RM; Chevret S; Abi-Rached J; Blanchet F; Dubertret L
    Arch Dermatol; 1996 Jun; 132(6):623-9. PubMed ID: 8651712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary syphilis on a psoriatic patient under cyclosporine: a challenging case.
    Pinto-Almeida T; Rosmaninho A; Sanches M; Alves R; Selores M
    Int J Dermatol; 2014 Jan; 53(1):e35-8. PubMed ID: 23330914
    [No Abstract]   [Full Text] [Related]  

  • 16. Low-dose, short-term ciclosporin (Neoral®) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients.
    Okubo Y; Natsume S; Usui K; Amaya M; Tsuboi R
    J Dermatol; 2011 May; 38(5):465-72. PubMed ID: 21352289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris.
    Kokelj F; Torsello P; Plozzer C
    J Eur Acad Dermatol Venereol; 1998 Mar; 10(2):143-6. PubMed ID: 9553911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal time for therapeutic drug monitoring of cyclosporine microemulsion in patients with psoriasis.
    Umezawa Y; Ozawa A
    Int J Dermatol; 2007 Jul; 46(7):763-6. PubMed ID: 17614813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine A microemulsion in dermatological practice: is oral solution better tolerated than soft gelatin capsules?
    Garcovich S; Garcovich C; Cassano N; Vena GA
    G Ital Dermatol Venereol; 2015 Aug; 150(4):473-4. PubMed ID: 26224233
    [No Abstract]   [Full Text] [Related]  

  • 20. Ophthalmic cyclosporine for the treatment of psoriatic conjunctivitis.
    Habeshian KA; Levitt JO
    J Am Acad Dermatol; 2014 Aug; 71(2):e43-4. PubMed ID: 25037807
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.